Skip to main content
Log in

Kristallarthropathien – alt, aber wichtig

Crystal-induced arthritis – old but important

  • CME Weiterbildung • Zertifizierte Fortbildung
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Zusammenfassung

Die Gicht ist die häufigste entzündliche Gelenkerkrankung des Mannes. Noch häufiger ist die Hyperurikämie, die asymptomatisch nicht medikamentös, sondern nur durch Diät behandelt wird. Erhöhte Harnsäurespiegel sind meist Folge einer renalen Ausscheidungsstörung, die überwiegend genetisch bedingt ist, aber auch erworben sein kann (Niereninsuffizienz, Diuretika). Erst mit dem meist typischen ersten Gichtanfall (Großzehengrundgelenk rot, heiß, höchst berührungsschmerzhaft) oder Nierensteinen bekommt die erhöhte Harnsäure Krankheitswert. Anfälle werden in der Regel mit NSAR oder Steroiden behandelt. Bei häufigen Anfällen, chronischer Gicht oder Gichtnephropathie ist eine zumindest 5 Jahre dauernde Urikostatikatherapie nötig, in der Regel mit Allopurinol oder demnächst mit Febuxostat. Anfangs ist zusätzlich eine Entzündungshemmung nötig. Die Kalziumpyrophosphatgicht, als zweithäufigste Erkrankung dieser Gruppe, wird durch Gelenkpunktion oder über die Chondrokalzinose diagnostiziert. Anfälle werden wie bei Gicht behandelt, eine kausale Therapie ist nur bei sekundären Formen (z. B. Hypothyreose, Hämochromatose, Hyperparathyroidismus) möglich.

Abstract

Gout is the most common inflammatory arthropathy for men. Asymptomatic hyperuricemia, which should lead to diet, but not to medication, is much more common still. Increased uric acid levels mostly result from diminished renal excretion, which is more commonly familiar than secondary (renal failure, diuretics). With the first episode of often typical (red, hot, exquisitely painful first MTP joint) acute arthritis or with urate nephrolithiasis, increased uric acid turns pathological. Attacks are treated with NSAIDs or corticosteroids. More common attacks, chronic gout, or urate nephropathy are definite indications for long-term (at least 5 years) therapy with allopurinol or febuxostat. Additional anti-inflammatory medication will be necessary during the first months. Calcium pyrophosphate deposition arthropathy, the second common crystal-induced arthritis, is diagnosed by synovial fluid analysis or for chondrocalcinosis. Treatment for attacks resembles therapy of acute gout; causal therapy is possible in case of secondary forms (e.g. hypothyroidism. hyperparathyroidism, hemochromatosis).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6

Literatur

  1. Arromdee E, Michet CJ, Crowson CS et al. (2002) Epidemiology of gout: is the incidence rising? J Rheumatol 29: 2403–2406

    PubMed  Google Scholar 

  2. Becker MA, Schumacher HR, Wortmann RL et al. (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353: 2450–2461

    Article  PubMed  CAS  Google Scholar 

  3. Chen LX, Schumacher HR (2006) Gout: can we create an evidence-based systematic approach to diagnosis and management? Best Pract Res Clin Rheumatol 20: 673–684

    Article  PubMed  Google Scholar 

  4. Fam AG (2000) What is new about crystals other than monosodium urate? Curr Opin Rheumatol 12: 228–234

    Article  PubMed  CAS  Google Scholar 

  5. Fernandez C, Noguera R, Gonzalez JA, Pascual E (1999) Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol 26: 2285–2286

    PubMed  CAS  Google Scholar 

  6. Graessler J, Graessler A, Unger S et al. (2006) Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum 54: 292–300

    Article  PubMed  CAS  Google Scholar 

  7. Groff GD, Franck WA, Raddatz DA (1990) Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 19: 329–336

    Article  PubMed  CAS  Google Scholar 

  8. Halverson PB, Derfus BA (2001) Calcium crystal-induced inflammation. Curr Opin Rheumatol 13: 221–224

    Article  PubMed  CAS  Google Scholar 

  9. Hung IF, Wu AK, Cheng VC et al. (2005) Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin Infect Dis 41: 291–300

    Article  PubMed  CAS  Google Scholar 

  10. Kramer HM, Curhan G (2002) The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988–1994. Am J Kidney Dis 40: 37–42

    Article  PubMed  Google Scholar 

  11. Maldonado I, Reginato AM, Reginato AJ (2001) Familial calcium crystal diseases: what have we learned? Curr Opin Rheumatol 13: 225–233

    Article  PubMed  CAS  Google Scholar 

  12. Moriwaki Y, Yamamoto T, Takahashi S et al. (2001) Spot urine uric acid to creatinine ratio used in the estimation of uric acid excretion in primary gout. J Rheumatol 28: 1306–1310

    PubMed  CAS  Google Scholar 

  13. Perez-Ruiz F, Atxotegi J, Hernando I et al. (2006) Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheum 55: 786–790

    Article  PubMed  CAS  Google Scholar 

  14. Roseff R, Wohlgethan JR, Sipe JD, Canoso JJ (1987) The acute phase response in gout. J Rheumatol 14: 974–977

    PubMed  CAS  Google Scholar 

  15. Schlesinger N, Schumacher R, Catton M, Maxwell L (2006) Colchicine for acute gout. Cochrane Database Syst Rev 4: CD006190

    PubMed  Google Scholar 

  16. Schueller-Weidekamm C, Schueller G, Aringer M et al. (2007) Impact of sonography in gouty arthritis: Comparison with conventional radiography, clinical examination, and laboratory findings. Eur J Radiol (Epub ahead of print)

  17. Terkeltaub R, Bushinsky DA, Becker MA (2006) Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther (Suppl 1) 8: S4

    Google Scholar 

  18. Underwood M (2006) Diagnosis and management of gout. BMJ 332: 1315–1319

    Article  PubMed  Google Scholar 

  19. Zhang W, Doherty M, Bardin T et al. (2006) EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65: 1312–1324

    Article  PubMed  CAS  Google Scholar 

  20. Zhang W, Doherty M, Pascual E et al. (2006) EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65: 1301–1311

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, das kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. Aringer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Winzer, M., Gräßler, J. & Aringer, M. Kristallarthropathien – alt, aber wichtig. Z. Rheumatol. 66, 317–325 (2007). https://doi.org/10.1007/s00393-007-0177-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-007-0177-1

Schlüsselwörter

Keywords

Navigation